Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar geeky1 (28.90) Submitted: 1/29/2007 8:24:54 PM : Outperform Start Price: $6.71 SNTS Score: -9.23

Hit bottom

Featured Broker Partners


Advertisement